K. Shariat

American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

Innovative therapies for systemic sclerosis

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis

cGMP in the Vasculature

Development of a provisional core set of response measures for clinical trials of systemic sclerosis

Systemic sclerosis

Changes in causes of death in systemic sclerosis, 1972–2002

The pathogenesis, diagnosis and treatment of Raynaud phenomenon

cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action

Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

The increase in pulmonary arterial pressure caused by hypoxia depends on iron status

Systemic sclerosis: hypothesis-driven treatment strategies

PDE5 inhibitors beyond erectile dysfunction

Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Cyclic GMP-Hydrolyzing Phosphodiesterases

Pulmonary Arterial Hypertension

Sildenafil for the treatment of Raynaud's phenomenon

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

Phosphodiesterase Inhibitors in Raynaud's Phenomenon

Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy